Cargando…

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients

BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates. METHODS: We identified biological markers accurately detected in a simple PE examina...

Descripción completa

Detalles Bibliográficos
Autores principales: Kremer, R, Best, L A, Savulescu, D, Gavish, M, Nagler, R M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853096/
https://www.ncbi.nlm.nih.gov/pubmed/20216542
http://dx.doi.org/10.1038/sj.bjc.6605607
_version_ 1782180007193346048
author Kremer, R
Best, L A
Savulescu, D
Gavish, M
Nagler, R M
author_facet Kremer, R
Best, L A
Savulescu, D
Gavish, M
Nagler, R M
author_sort Kremer, R
collection PubMed
description BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates. METHODS: We identified biological markers accurately detected in a simple PE examination. We analysed data from 19 patients diagnosed with lung cancer (nine adeno-Ca, five non-small-cell Ca (not specified), four squamous-cell Ca, one large-cell Ca) and 22 patients with benign inflammatory pathologies: secondary to trauma, pneumonia or TB. RESULTS: Pleural effusion concentrations of seven analysed biological markers were significantly lower in lung cancer patients than in benign inflammatory patients, especially in matrix metalloproteinase (MMP)-9, MMP-3 and CycD1 (lower by 65% (P<0.000003), 40% (P<0.0007) and 34% (P<0.0001), respectively), and in Ki67, ImAnOx, carbonyls and p27. High rates of sensitivity and specificity values were found for MMP-9, MMP-3 and CycD1: 80 and 100% 87 and 73% and 87 and 82%, respectively. CONCLUSION: Although our results are of significant merit in both the clinical and pathogenetic aspects of lung cancer, further research aimed at defining the best combination for marker analysis is warranted. The relative simplicity in analysing these markers in any routine hospital laboratory may result in its acceptance as a new diagnostic tool.
format Text
id pubmed-2853096
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-28530962011-03-30 Pleural fluid analysis of lung cancer vs benign inflammatory disease patients Kremer, R Best, L A Savulescu, D Gavish, M Nagler, R M Br J Cancer Molecular Diagnostics BACKGROUND: Correct diagnosis of pleural effusion (PE) as either benign or malignant is crucial, although conventional cytological evaluation is of limited diagnostic accuracy, with relatively low sensitivity rates. METHODS: We identified biological markers accurately detected in a simple PE examination. We analysed data from 19 patients diagnosed with lung cancer (nine adeno-Ca, five non-small-cell Ca (not specified), four squamous-cell Ca, one large-cell Ca) and 22 patients with benign inflammatory pathologies: secondary to trauma, pneumonia or TB. RESULTS: Pleural effusion concentrations of seven analysed biological markers were significantly lower in lung cancer patients than in benign inflammatory patients, especially in matrix metalloproteinase (MMP)-9, MMP-3 and CycD1 (lower by 65% (P<0.000003), 40% (P<0.0007) and 34% (P<0.0001), respectively), and in Ki67, ImAnOx, carbonyls and p27. High rates of sensitivity and specificity values were found for MMP-9, MMP-3 and CycD1: 80 and 100% 87 and 73% and 87 and 82%, respectively. CONCLUSION: Although our results are of significant merit in both the clinical and pathogenetic aspects of lung cancer, further research aimed at defining the best combination for marker analysis is warranted. The relative simplicity in analysing these markers in any routine hospital laboratory may result in its acceptance as a new diagnostic tool. Nature Publishing Group 2010-03-30 2010-03-09 /pmc/articles/PMC2853096/ /pubmed/20216542 http://dx.doi.org/10.1038/sj.bjc.6605607 Text en Copyright © 2010 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Kremer, R
Best, L A
Savulescu, D
Gavish, M
Nagler, R M
Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title_full Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title_fullStr Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title_full_unstemmed Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title_short Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
title_sort pleural fluid analysis of lung cancer vs benign inflammatory disease patients
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853096/
https://www.ncbi.nlm.nih.gov/pubmed/20216542
http://dx.doi.org/10.1038/sj.bjc.6605607
work_keys_str_mv AT kremerr pleuralfluidanalysisoflungcancervsbenigninflammatorydiseasepatients
AT bestla pleuralfluidanalysisoflungcancervsbenigninflammatorydiseasepatients
AT savulescud pleuralfluidanalysisoflungcancervsbenigninflammatorydiseasepatients
AT gavishm pleuralfluidanalysisoflungcancervsbenigninflammatorydiseasepatients
AT naglerrm pleuralfluidanalysisoflungcancervsbenigninflammatorydiseasepatients